Abstract
The current status of the evaluation of many neoplasias (e.g., carcinoma of the prostate), relies on analysis of tumor stage and/or grade to predict the outcome of disease. Recent developments in screening practices with circulating markers, such as prostate-specific antigen (PSA), has led to the diagnosis of preneoplastic and early neoplastic lesions (1–4). Although it is generally thought that these very early lesions will eventually progress to malignant disease, it is not always the case. In the early lesions, staging and grading of tumors has not predicted eventual outcome with any certainty. For this reason, other surrogate biomarkers have been sought to help distinguish potential bad outcomes from those that do not progress and therefore need no intervention. Surrogate biomarker analysis of neoplasia can involve measurement of protein species, and several markers have been associated with specific neoplastic conditions (5–8). Alternatives to protein analysis include genetic-instability determinations (9–12) or mRNA analysis for molecules, such as growth factors/ proto-oncogenes (13–15). Assaying mRNA makes sense if the gene of interest does not encode for proteins against which antibodies are currently available, when those genes are controlled primarily at the level of transcription of mRNA, or if protein assays are insensitive. Analysis of mRNA has classically used Northern blot assays, which suffer from sensitivity problems, or RNA protection assays (SI nuclease assay or RNase protection assay), which are more sensitive than Northern blotting, but are still relatively insensitive. With the advent of the polymerase chain reaction (PCR), attempts have been made to first measure DNA (16–18) and then RNA markers for disease (13–15).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lee C T. and Oesterling J E (1995) Diagnostic markers of prostate cancer utility of prostate specific antigen in diagnosis and staging. Sent Surg Oncol 11, 23–35
Kardamakis D. (1996) Tumor serum markers, clinical and economical aspects Anticancer Res 16, 2285–2288
Bangma C. H, Blijenberg B G, and SchroderF H (1995) Prostate specific antigen, its clinical use and application in screening for prostate cancer Scand J Clin Lab Invest 111, 35–44
Randrup E. and Baum N. (1996) Prostate specific antigen testing for prostate cancer. Practical interpretation of values Postgrad Med. 99, 227–234.
Suresh M R (1996) Classification of tumor markers. Anticancer Res 16, 2273–2277.
Pamies R. J and Crawford D R (1996) Tumor markers. An update Med Clin North Am. 80, 185–199
Grignon D J. and Hammond E H (1995) College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors Report of the prostate cancer working group Arch Path Lab Med 119, 1122–1126.
Berek J S and Bast R. C (1995) Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection Cancer 76, 2092–2096
Tahara E (1995) Genetic alterations in human gastrointestinal cancers The application to molecular diagnosis Cancer 75, 1410–1417
Svendsen L B (1993) Congenital genetic instability in colorectal carcinomas Danish Med Bull 40, 546–556.
Weinert T and Lydall D (1993) Cell cycle checkpoints, genetic instability and cancer Sem Cancer Biol 4, 129–140.
Thibodeau S., Bren G., and Schaid D. (1993) Microsatelhte instability in cancer of the proximal colon Science 260, 816–819.
Ciardiello F, Kim N, McGeady M L., Liscia D S., Saeki T, Bianco C, and Salomon D. S (1991) Expression of transforming growth factor alpha in breast cancer. Annal Oncol 2, 169–182
Klimpfinger M, Zisser G., Ruhri C, Putz B, Steindorfer P, and Hofier H (1990) Expression of c-myc and c-fos mRNA in colorectal carcinoma in man Virchows Archiv B Cell Pathol. Mol Pathol 59, 165–171
Melo J V. (1996) The molecular biology of chronic myeloid leukemia Leukemia 10, 751–756
Thein S L., Jeffreys A. J, Gooi H C, Cotter F, Flint J, O’Connor N. T J, Weatherall D J, and Wainscoat J S. (1993) Detection of somatic changes in human cancer DNA by DNA fingerprint analysis 8/3/2006 10:01PM 55, 816–819
Peinado M A., Malkhosyan S., Velazquez A., and Perucho M. (1992) Isolation and characterization of allehc losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. Proc Natl Acad Sci USA 89, 10,065–10,069
Meling G. I., Lothe R. A, Borresen A. L., Hauge S., Graue C, Clausen O. P., and Rognum T. O. (1991) Genetic alterations within the retinoblastoma locus in colorectal carcinomas Relation to DNA ploidy pattern studied by flow cytometric analysis Br J. Cancer 64, 475–480
Becker-Andre M and Hahlbrook K (1989) Absolute mRNA quantification using the polymerase chain reaction (PCR). A novel approach by a PCR aided transcript titration assay (PATTY). Nucleic Acids Res 17, 9437–9446.
Piatek M, Saag M. S., Yang L C, Clark S. J., Kappes J. C, Luk K C Hahn B. H., Shaw G. M., and Lifson J. D (1993) High levels of HIV-I in plasma during all stages of infection determined by competitive PCR Science 259, 1749–1754
Piatek M, Luk K. C Williams B, and Lifson J D. (1993) Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. Biotechniques 14, 70–81.
Menzo S., Bagnarelli P, Giacca M, and Varal A (1992) Absolute quantitation of viremia in human immunodeficiency virus infection by competitive reverse transcription and polymerase chain reaction J Clin Microbiol 30, 1752–1757
Scadden D. T., Wang Z, and Groopman J E. (1992) Quantitation of plasma human immunodeficiency virus type 1 RNA by competitive polymerase chain reaction J Infect Dis 165, 1119–1123.
Wang A. M, Doyle M V, and Mark D. F (1989) Quantitation of mRNA by the polymerase chain reaction Proc Natl. Acad Sci USA 86, 9717–9721.
Gilliland G, Perrin S, Blanchard K., and Bunn H. F (1990) Analysis of cytokine mRNA and DNA. detection and quantitation by competitive polymerase chain reaction. Proc Natl Acad Sci USA 87, 2725–2729.
Bagnarelli P, Menso S, Valenia A, Manzin A., Giacca M., Ancarani F, Scalise G, Varaldo P E., and Clementi M. (1992) Molecular profile of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS. J Virol 66, 7328–7335.
Chomczynski P. and Sacchi N (1987) Single step method of RNA isolation by acid guanidiniumthiocyanate phenol-chloroform extraction. Anal Biochem 162, 156–159
Hockett R D., Janowski K. M, and Bucy R. P (1995) Simultaneous quantitation of multiple cytokine mRNAs by RT-PCR utilizing plate based EIA methodology. J Immunol Meth 187, 273–285
Richardson J. P and Macy M R. (1981) Ribonucleic acid synthesis termination protein rho function: effects of conditions that destabilize ribonucleic acid secondary structure Biochemistry 20, 1133–1139
Alford R L. and Belmont J W (1990) Stable RNA secondary structure in a retroviral vector insert terminates reverse transcriptase elongation in vitro but not in cultured cells. Hum. Gene Ther 1, 269–276.
Forough R, Engleka K, Thompson J A, Jackson A, Imamura T, and Maciag T. (1991) Differential expression in Eschenchia coli of the alpha and beta forms of hepann binding acidic fibroblast growth factor-1 · potential role of RNA secondary structure Biochim Biophys. Acta 1090, 293–298
Berkhout B., Gatignol A., Silver J, and Jeang K. T. (1990) Efficient trans activation by the HIV-2 Tat protein requires a duplicated TAR RNA structure. Nucleic Acids Res 18, 1839–1846
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Humana Press Inc, Totowa, NJ
About this protocol
Cite this protocol
Hockett, R.D., Rogers, M.D., Srivastava, S. (1998). Quantitative, Competitive RT-PCR Analysis of Biomarkers in the Study of Neoplasia. In: Hanausek, M., Walaszek, Z. (eds) Tumor Marker Protocols. Methods in Molecular Medicine™, vol 14. Springer, Totowa, NJ. https://doi.org/10.1385/0-89603-380-5:373
Download citation
DOI: https://doi.org/10.1385/0-89603-380-5:373
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-0-89603-380-1
Online ISBN: 978-1-59259-598-3
eBook Packages: Springer Protocols